Myrelez (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Myrelez, is a somatostatin analog presented as a subcutaneous formulation for injection use. It is employed to control excess growth hormone secretion in acromegaly and to manage hormone‑producing neuroendocrine tumors.

GNH USA supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Myrelez is a somatostatin analog used in disorders characterized by excess hormone secretion. - Acromegaly: normalises elevated growth hormone levels and reduces associated symptoms. - Gastroenteropancreatic neuroendocrine tumors: inhibits tumor‑related peptide hormone release and may slow disease progression. - Carcinoid syndrome: alleviates flushing, diarrhoea and other hormone‑driven symptoms associated with neuroendocrine tumours.

Adverse reactions may occur with lanreotide therapy.

Common Side Effects: - Injection site pain or erythema - Diarrhoea - Nausea - Abdominal discomfort - Headache - Hyperglycaemia

Serious or Rare Side Effects: - Gallbladder disease or cholelithiasis - Acute pancreatitis - Severe hyperglycaemia requiring medical intervention - Anaphylactic or severe allergic reactions

Lanreotide should be used with careful clinical monitoring. - Monitor glucose levels: risk of hyperglycaemia may require antidiabetic therapy adjustment. - Assess gallbladder status: patients are prone to gallstone formation. - Evaluate liver function: hepatic metabolism may be altered in impairment. - Use caution in severe renal impairment: dose may need modification. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may interact with several drug classes.

Major Interactions (Avoid): - Other somatostatin analogues: combined use can cause excessive hormone suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lanreotide exposure.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: lanreotide can raise blood glucose, requiring dose adjustments. - Medications affecting gallbladder motility (e.g., estrogen therapy): may increase gallstone risk. - QT‑prolonging drugs: monitor cardiac rhythm for additive effects.